Risk factors

The company faces emerging risks from incorporating artificial intelligence and machine learning technologies into its products and operations.

MapLight Therapeutics relies heavily on external funding, having completed an IPO on October 26, 2025, raising $261.6 million net proceeds.

M-tron added new risk disclosures regarding U.S. government defense spending and trade policy tariffs following its spin-off.

MetaVia faces heavy concentration risk with Dong-A ST and Dong-A Holdings controlling 35 percent of voting rights.

Noodles & Co initiated a strategic review exploring a sale or refinancing on September 3, 2025.

Newsmax added risks regarding third-party cloud technology, payment processing friction, and Class B stock sales dilution. Going concern and Smartmatic litigation risks were removed.

Concentration risk deepened as one customer grew to 32.2% of net sales in 2025. New credit facility established with Associated Bank featuring a $15,000 revolving credit facility and $2,200 term loan. Stock trading below net equity value triggered long-lived asset impairment evaluation.

The company received an FDA not-approvable letter for the VenoValve PMA application on August 19, 2025. The FDA cited insufficient hemodynamic correlation and surgical safety concerns, highlighting regulatory hurdles.

Oramed faces significant risks from ongoing clinical trial uncertainties for its oral insulin capsule and heavy reliance on strategic investments like Alpha Tau and Scilex loans. The company also implemented a poison pill defense and maintains extensive operations and research activities in Israel.

P3 Health Partners faces heightened regulatory scrutiny in California, ongoing solvency and compliance challenges, and emerging legal risks around AI technologies.

Accumulated deficit grew to $71.0 million by December 31, 2025, raising going concern doubts.

Rani Therapeutics highlights new partnership risks with Chugai, NASDAQ listing compliance concerns, and international trade tariff uncertainties.